+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ponatinib Tablets Market - Global Forecast to 2030- Product Image
Ponatinib Tablets Market - Global Forecast to 2030- Product Image
Sale

Ponatinib Tablets Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6119235
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Ponatinib tablets are transforming the hematologic oncology market by addressing resistant forms of leukemia through advanced targeted therapy. Senior decision-makers are navigating an evolving environment shaped by technological progress, regulatory adaptation, and shifting global supply chain dynamics.

Market Snapshot: Ponatinib Tablets

Ponatinib tablets represent a compelling innovation in the treatment of challenging hematologic malignancies, particularly for cases resistant to earlier therapies. Since entering the market, ponatinib has shifted treatment paradigms for Philadelphia chromosome-positive leukemias, providing a crucial option for patients with limited choices. With a market defined by rapid advances in molecular diagnostics and precision oncology, ponatinib is at the forefront of next-generation targeted therapies. The sector demonstrates strong clinical uptake due to improved patient outcomes and its utility in refractory cases. Stakeholders face a landscape marked by adaptive regulatory changes, expansion of payer mechanisms, and increased integration of digital health solutions to enhance monitoring and adherence.

Ponatinib Tablets Market Scope & Segmentation

  • Indication: Acute lymphoblastic leukemia (Philadelphia chromosome-positive), chronic myeloid leukemia (accelerated phase, blast crisis, chronic phase)
  • Treatment Line: First-line, second-line, third-line and beyond (including non-T315I mutation, T315I mutation)
  • Dosage Strength: 15 mg, 30 mg, 45 mg
  • Distribution Channel: Hospital pharmacies, online pharmacies, retail pharmacies
  • End User: Homecare, hospitals, specialty clinics
  • Packaging Type: Blisters, bottles
  • Region: Americas, Europe, Middle East & Africa, Asia-Pacific
  • Countries/Sub-Regions: United States (California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio), Canada, Mexico, Brazil, Argentina, United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland, China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan
  • Key Players: Takeda Pharmaceutical Company Limited, ARIAD Pharmaceuticals, Inc.

Advanced technologies such as digital platforms and precision diagnostics are increasingly integral to optimizing patient selection and supporting real-world monitoring in diverse care environments.

Ponatinib Tablets: Key Takeaways for Decision Makers

  • Ponatinib targets BCR-ABL tyrosine kinase, inhibiting resistant mutations and reshaping protocols for refractory and relapsed leukemia cases.
  • Genomic profiling adoption is expanding, improving identification of patients suitable for high-potency therapy and supporting broader precision medicine goals.
  • Evolving regulatory collaboration is accelerating approvals and supporting faster patient access, driven by safety-focused frameworks and real-world evidence collection.
  • Distribution strategies are adapting with expanded online pharmacy channels and integration with specialty care settings to address diverse patient needs.
  • Increasing presence of generic manufacturers is intensifying competitive dynamics, pushing established brands to invest in patient support, adherence programs, and digital health engagement.

Tariff Impact: Navigating US Supply Chain Pressures

The 2025 introduction of elevated US tariffs on active pharmaceutical ingredients required for ponatinib tablets has prompted significant adjustments. Manufacturers are shifting sourcing strategies, considering domestic partners, and adopting cost-containment measures to preserve production stability. Investments in local infrastructure and supply chain resilience are strengthening operational continuity, while providers and payers remain attentive to potential pricing pressures and advocate for increased transparency.

Methodology & Data Sources

This analysis employs a multi-stage methodology, combining peer-reviewed literature, regulatory documentation, clinical trial databases, and primary insights from interviews with KOLs in hematology, pharmacy, payer, and supply chain roles. Segmentation and market trends were triangulated and confirmed via expert advisory boards. A comprehensive quality review process was completed to ensure accuracy and analytical rigor.

Why This Report Matters

  • Supports leadership teams with evidence-driven guidance to optimize market strategies for ponatinib tablets amid evolving clinical and regulatory environments.
  • Equips stakeholders to manage supply chain complexities, regulatory shifts, and competitive pressures in global oncology markets.
  • Provides actionable segmentation insights and regional intelligence, aiding resource allocation and strategic planning for growth and risk mitigation.

Conclusion

Ponatinib tablets continue to drive pivotal changes in the targeted oncology landscape. Industry players attuned to regional variations, advances in technology, and collaboration will be best positioned to capture emerging opportunities. Ongoing vigilance and data-backed actions are essential for sustaining success in this sector.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Strategies adopted by pharmaceutical companies to expand ponatinib tablet indications in resistant CML and ALL patient populations
5.2. Analysis of real-world safety monitoring data for ponatinib in post-marketing surveillance programs across Europe and North America
5.3. Impact of accelerated FDA and EMA approval pathways on global ponatinib market entry timelines and pricing strategies
5.4. Assessment of novel companion diagnostics to optimize ponatinib treatment selection in T315I-mutated chronic myeloid leukemia patients
5.5. Manufacturer pricing negotiations and patient assistance programs shaping ponatinib affordability in emerging Asian and Latin American markets
5.6. Clinical trial outcomes for ponatinib combination regimens targeting multi-resistant Philadelphia chromosome-positive leukemia subtypes
5.7. Supply chain challenges and API sourcing strategies influencing ponatinib tablet production costs and global distribution lead times
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Ponatinib Tablets Market, by Indication
8.1. Introduction
8.2. Acute Lymphoblastic Leukemia
8.2.1. Philadelphia Chromosome Positive
8.3. Chronic Myeloid Leukemia
8.3.1. Accelerated Phase
8.3.2. Blast Crisis
8.3.3. Chronic Phase
9. Ponatinib Tablets Market, by Treatment Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line And Beyond
9.4.1. Non-T315I Mutation
9.4.2. T315I Mutation
10. Ponatinib Tablets Market, by Dosage Strength
10.1. Introduction
10.2. 15 Mg
10.3. 30 Mg
10.4. 45 Mg
11. Ponatinib Tablets Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Ponatinib Tablets Market, by End User
12.1. Introduction
12.2. Homecare
12.3. Hospitals
12.4. Specialty Clinics
13. Ponatinib Tablets Market, by Packaging Type
13.1. Introduction
13.2. Blisters
13.3. Bottles
14. Americas Ponatinib Tablets Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Ponatinib Tablets Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Ponatinib Tablets Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Takeda Pharmaceutical Company Limited
17.3.2. ARIAD Pharmaceuticals, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PONATINIB TABLETS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PONATINIB TABLETS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PONATINIB TABLETS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PONATINIB TABLETS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PONATINIB TABLETS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PONATINIB TABLETS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PONATINIB TABLETS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. PONATINIB TABLETS MARKET: RESEARCHAI
FIGURE 28. PONATINIB TABLETS MARKET: RESEARCHSTATISTICS
FIGURE 29. PONATINIB TABLETS MARKET: RESEARCHCONTACTS
FIGURE 30. PONATINIB TABLETS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PONATINIB TABLETS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PONATINIB TABLETS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PONATINIB TABLETS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PONATINIB TABLETS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PONATINIB TABLETS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PONATINIB TABLETS MARKET SIZE, BY PHILADELPHIA CHROMOSOME POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PONATINIB TABLETS MARKET SIZE, BY PHILADELPHIA CHROMOSOME POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PONATINIB TABLETS MARKET SIZE, BY ACCELERATED PHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PONATINIB TABLETS MARKET SIZE, BY ACCELERATED PHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PONATINIB TABLETS MARKET SIZE, BY BLAST CRISIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PONATINIB TABLETS MARKET SIZE, BY BLAST CRISIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PONATINIB TABLETS MARKET SIZE, BY CHRONIC PHASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PONATINIB TABLETS MARKET SIZE, BY CHRONIC PHASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PONATINIB TABLETS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PONATINIB TABLETS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PONATINIB TABLETS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PONATINIB TABLETS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PONATINIB TABLETS MARKET SIZE, BY NON-T315I MUTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PONATINIB TABLETS MARKET SIZE, BY NON-T315I MUTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PONATINIB TABLETS MARKET SIZE, BY T315I MUTATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PONATINIB TABLETS MARKET SIZE, BY T315I MUTATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PONATINIB TABLETS MARKET SIZE, BY 15 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PONATINIB TABLETS MARKET SIZE, BY 15 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PONATINIB TABLETS MARKET SIZE, BY 30 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PONATINIB TABLETS MARKET SIZE, BY 30 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PONATINIB TABLETS MARKET SIZE, BY 45 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PONATINIB TABLETS MARKET SIZE, BY 45 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PONATINIB TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PONATINIB TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PONATINIB TABLETS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PONATINIB TABLETS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PONATINIB TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PONATINIB TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PONATINIB TABLETS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PONATINIB TABLETS MARKET SIZE, BY HOMECARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PONATINIB TABLETS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PONATINIB TABLETS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PONATINIB TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PONATINIB TABLETS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PONATINIB TABLETS MARKET SIZE, BY BLISTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PONATINIB TABLETS MARKET SIZE, BY BLISTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PONATINIB TABLETS MARKET SIZE, BY BOTTLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PONATINIB TABLETS MARKET SIZE, BY BOTTLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES PONATINIB TABLETS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 111. CANADA PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 112. CANADA PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 113. CANADA PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 114. CANADA PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 115. CANADA PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 116. CANADA PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 117. CANADA PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 118. CANADA PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 119. CANADA PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 120. CANADA PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 121. CANADA PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 122. CANADA PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 123. CANADA PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. CANADA PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. CANADA PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. CANADA PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. CANADA PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 128. CANADA PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 132. MEXICO PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 133. MEXICO PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 134. MEXICO PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 135. MEXICO PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 136. MEXICO PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 137. MEXICO PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 138. MEXICO PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 139. MEXICO PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 140. MEXICO PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 141. MEXICO PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. MEXICO PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. MEXICO PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. MEXICO PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. MEXICO PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 146. MEXICO PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA PONATINIB TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 221. GERMANY PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 222. GERMANY PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 223. GERMANY PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 224. GERMANY PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 225. GERMANY PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 226. GERMANY PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 227. GERMANY PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 228. GERMANY PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 229. GERMANY PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 230. GERMANY PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 231. GERMANY PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 232. GERMANY PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 233. GERMANY PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. GERMANY PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. GERMANY PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. GERMANY PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. GERMANY PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 238. GERMANY PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 239. FRANCE PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 240. FRANCE PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 241. FRANCE PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 242. FRANCE PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 243. FRANCE PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 244. FRANCE PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 245. FRANCE PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 246. FRANCE PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 247. FRANCE PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 248. FRANCE PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 249. FRANCE PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 250. FRANCE PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 251. FRANCE PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. FRANCE PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. FRANCE PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. FRANCE PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. FRANCE PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 256. FRANCE PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 275. ITALY PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. ITALY PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. ITALY PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 278. ITALY PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 279. ITALY PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 280. ITALY PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 281. ITALY PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 282. ITALY PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 283. ITALY PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 284. ITALY PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 285. ITALY PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 286. ITALY PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 287. ITALY PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. ITALY PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. ITALY PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. ITALY PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. ITALY PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 292. ITALY PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 293. SPAIN PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 294. SPAIN PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 295. SPAIN PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 296. SPAIN PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 297. SPAIN PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 298. SPAIN PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 299. SPAIN PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 300. SPAIN PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 301. SPAIN PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 302. SPAIN PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 303. SPAIN PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 304. SPAIN PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 305. SPAIN PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. SPAIN PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. SPAIN PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. SPAIN PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. SPAIN PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 310. SPAIN PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
TABLE 328. UNITED ARAB EMIRATES PONATINIB TABLETS MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 330. SAUDI ARABIA PONATINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 332. SAUDI ARABIA PONATINIB TABLETS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA PONATINIB TABLETS MARKET SIZE, BY CHRONIC MYELOI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Ponatinib Tablets market report include:
  • Takeda Pharmaceutical Company Limited
  • ARIAD Pharmaceuticals, Inc.

Related Topics

Related Reports

Chronic Myelogenous Leukemia Therapeutics Market - Global Forecast 2025-2030 - Product Image

Chronic Myelogenous Leukemia Therapeutics Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
TKI for Chronic Myeloid Leukemia Market - Global Forecast 2025-2030 - Product Image

TKI for Chronic Myeloid Leukemia Market - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Acute Lymphoblastic Leukemia Therapeutics Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034) - Product Image

Acute Lymphoblastic Leukemia Therapeutics Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 350 Pages
  • Global
From
Sprycel Global Market Report 2025 - Product Image

Sprycel Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Dasatinib Drugs Market Report 2025 - Product Image

Dasatinib Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.